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Abstract
Introduction: Type 1 diabetes (T1D) impacts many individuals around the world. Treatment
goals of T1D include lowering hemoglobin A1c (HbA1c) values while minimizing the time
spent in hypoglycemia. Frequent glucose monitoring is required to achieve optimal glycemic
control.
Background: HbA1c has been used for many years to track glycemic control. When discussing
care of older adults, hypoglycemia is a more important marker to track. The risks associated with
hypoglycemia are higher among older adults with T1D than the general population.
Multimorbidity, polypharmacy, and age-related mental decline increase the likelihood and
danger of severe hypoglycemic episodes. Self-monitoring blood glucose (SMBG) provides
point-in-time glucose measurements. Continuous glucose monitors (CGM) are wearable devices
that transmit continuous glucose measurements throughout the day. Variations in glucose are
viewed in real time, and users can be alerted when glucose levels are dangerously high or low.
Methods: A literature search was completed to assess the benefits of CGM use in older adults.
The PubMed database was used to identify relevant articles.
Discussion: CGM devices show greater improvements in HbA1c and greater reductions in
hypoglycemia over SMBG. Health-related quality of life is also seen to increase with use. Given
the significant effects of CGM use on hypoglycemia, the devices should be recommended for use
in all older adults with T1D.
Conclusion: Further research is needed to evaluate the benefits of CGM use in various
subpopulations of older adults. Reasons for limited use in this population should also be explored
with the goal of increasing accessibility and usability.
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Introduction
Type 1 diabetes (T1D) is a multifactorial disease affecting 1.6 million Americans and
many more, worldwide.1 Over recent years, the landscape of the T1D population has been
changing. For unidentified reasons, incidence and prevalence of the disease has been increasing
worldwide.2,3 Furthermore, as technology and treatment regimens undergo changes and progress,
more patients with T1D are living longer and the proportion of older adults living with T1D is
increasing.2 While there is a large amount of research on T1D in younger populations, largescale research focusing on management in older adults has previously been lacking. Age-related
mental decline, multimorbidity, and more physical and social limitations differentiate this
population from others. The unique needs of elderly individuals combined with the complicated
management of T1D requires an intersectional approach to care.
T1D results in an absolute deficiency in endogenous insulin due to the autoimmunemediated destruction of islet β-cells in the pancreas. Without insulin production, patients will
develop hyperglycemia, leading to acute conditions such as diabetic ketoacidosis and long-term
sequelae including nephropathy, neuropathy, retinopathy, atherosclerotic cardiovascular disease,
and cerebrovascular disease.4,5 Exogenous insulin administration is required for management
and, unfortunately, introduces the risk of hypoglycemia. Effects of hypoglycemia can range from
confusion and discomfort to life-threatening cardiac abnormalities and death.6
An integral component of T1D management from diagnosis through end of life is the
monitoring of blood glucose levels throughout the day with an optimal glucose range between 70
and 180 mg/dL.7 Frequent monitoring of blood glucose allows individuals to adjust carbohydrate
intake and exogenous insulin administration appropriately.8,9 For several decades the standard of
care has been centered around self-monitoring blood glucose (SMBG) with a glucometer,
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allowing individuals to obtain point-in-time plasma glucose concentrations. The advent of
continuous glucose monitoring (CGM) has expanded patients’ ability to understand their own
glycemic patterns and has shown measurable improvement in care within the general T1D
population.10–12 Within the past 5 years, CGM has become more user friendly, gained important
FDA clearances, and has been approved for use by patients on Medicare.13,14 For older adults
with T1D, limiting hypoglycemia has become as a priority.7 As more patients with T1D age, the
current available glucose monitoring systems must be evaluated for their impact on
hypoglycemia in this age group.
Background: Literature Review
Hemoglobin A1c as a Marker for Control
Hemoglobin A1c (HbA1c) has long been used as a marker for glycemic control in T1D.
The value represents the degree of glycation of hemoglobin, and thus gives an indirect measure
of free glucose in the blood. HbA1c values are seen to be higher in patients who experience more
glycemic variability, and studies have shown that HbA1c levels may also be used to estimate
average blood glucose values in T1D and type 2 diabetes (T2D).5,15 The American Diabetes
Association (ADA) recommends routine monitoring of HbA1c two to four times per year for
T1D and T2D patients and sets less than 7.0% as the target level for nonpregnant individuals
with diabetes.7 A retrospective observational study by Pettus et al.5 in 2019 illustrated the
predictive value of HbA1c on several serious complications associated with T1D. Increasing
HbA1c values were consistently associated with higher rates of diabetic ketoacidosis (DKA),
severe hypoglycemia, neuropathy, and nephropathy, with markedly higher rates occurring at
HbA1c values greater than 9.0%.
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Hypoglycemia
Hypoglycemia is most commonly defined as blood glucose less than 70 mg/dL, and it is a
serious complication that occurs in T1D due to the patients’ reliance on exogenous insulin.
Asymptomatic and moderately symptomatic hypoglycemic episodes are common, whereas
severe hypoglycemic episodes are less frequent. For the purposes of this paper and the studies
described within, severe hypoglycemia is not tied to a specific glucose value, but is instead an
individualized event in which the person loses consciousness or requires another person to assist
them in resolving the hypoglycemia.11,16,17 The condition has been associated with negative acute
and chronic effects and greatly impacts the quality of life of individuals with T1D. Several acute
symptoms can be attributed to the physiologic stress response triggered by low blood glucose.6
The autoimmune destruction of pancreatic β-cells seen in T1D produces an associated defect in
glucagon secretion by α-cells, causing the body to rely more on a response by the sympathetic
nervous system and catecholamine release to raise blood glucose.6,18 The sympathetic stress
response produces tachycardia and widened arterial pulse pressure, and may lead to lengthening
of the QTc interval and arrhythmias in cases of severe hypoglycemia.2,6 The danger of the
potential cardiac abnormalities due to hypoglycemia is compounded by a concurrent risk for
acute coagulopathies and contributes to the risk of fatality with hypoglycemia. Acute
hypoglycemia has been shown to contribute to 10% of deaths under 40 years of age in
individuals with T1D.6
Given the acute dangers associated with hypoglycemia, awareness of hypoglycemia must
be discussed. Impaired awareness of hypoglycemia is seen in 25% of those with T1D.19
Individuals with severely reduced subjective awareness are described as having a syndrome of
impaired awareness (SIA) and are at a 20-fold increased risk of a severe hypoglycemic episode.18
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The most common etiology for SIA is a history of recurrent hypoglycemic episodes. Frequent
exposure to hypoglycemia lowers the threshold concentration for plasma glucose at which
autonomic counterregulatory processes are initiated. Additionally, those with SIA demonstrate
changes in the brain in areas involved in interoception.6 Whether a person exhibits SIA or not,
they are at increased risk for hypoglycemia overnight because deep sleep also inhibits the
counterregulatory autonomic response. Thus, overnight episodes may be asymptomatic and
remain undetected. Without the physiologic response to wake them, people are unable to treat
their hypoglycemia. As a result, they are at greater risk for a nocturnal severe hypoglycemic
episode. More than 50% of severe hypoglycemic episodes in people with T1D occur overnight.6
As a result, fear of hypoglycemia is a common finding in T1D. An analysis by Martyn-Nemeth20
in 2018 showed that fear of hypoglycemia is significantly associated with a decrease in sleep
quality. Those with SIA or frequent hypoglycemia may also be at risk for losing driving
privileges and being restricted in their employment opportunities.6
The effect of hypoglycemia on cognition is multifactorial. Acute effects of confusion,
irrational behaviors, and drowsiness are seen in hypoglycemic episodes. More serious
complications including seizures and coma are possible in cases of severe hypoglycemia.6
Multiple studies have shown it to affect memory. Immediate memory, working memory, and the
consolidation of memory can be impaired acutely during hypoglycemic episodes. Decreases in
global cognitive function, especially in regards to slowing of cerebration and performance have
been associated with hypoglycemia and are seen more in cases of repeated episodes.2,6 In 2014,
Ryan et al.21 conducted a follow-up study of the Wisconsin Epidemiologic Study of Diabetic
Retinopathy (WESDR) longitudinal cohort group to assess cognitive function in adults with
T1D. The study revealed that an episode of severe hypoglycemia within the past 12 months was
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associated with worse nonverbal memory and mental efficiency. Mental efficiency was also
worsened by hyperglycemic complications including decreased retinal arteriolar and venular
diameters and carotid artery plaques.21
Considerations for Older Adults
In regards to the older adult, the management of T1D is more specialized to limiting
hypoglycemia, rather than preventing microvascular and macrovascular complications associated
with high blood glucose. In terms of care guidelines, the ADA relaxes the goal HbA1c level to <
8.0% in older adults with impaired awareness of hypoglycemia and multiple comorbidities, in
contrast to the goal of < 7.0% in healthy, nonpregnant adults.7 This is done according to the
assumption that lower HbA1c values are correlated with a lower mean plasma glucose, and is
therefore associated with a greater risk of hypoglycemia.22 However, more focused research in
older adults with T1D has revealed that hypoglycemia and severe hypoglycemia occur more
frequently with age, both in older adults with HbA1c less than 7.5% and less than 8.0%.2
The increased risks for hypoglycemia can be partially attributed to the effects of
polypharmacy and multimorbidity seen in older adults. Age-related changes in metabolism lead
to greater and more unpredictable drug effects. Pain medications cause confusion and
coordination changes which could affect insulin self-management, and the use of non-selective
β-blockers has been associated with higher rates of severe hypoglycemia.2 With increased
duration of T1D, higher incidences of microvascular complications are seen, and nephropathy
and neuropathy have also been associated with increased rates of severe hypoglycemia.2,5 In
2020, McCoy et al published a cohort study using claims data from 201,705 adults with T1D and
T2D which investigated risks for hypoglycemia-related emergency department visits and
hospitalizations. Risks identified as being significant included age greater than 75 years, T1D
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diagnosis, patients with multiple comorbidities, and previous hypoglycemia-related ED visit or
hospitalization.23
As impaired awareness of hypoglycemia has been shown to increase the risk of severe
episodes in all adults with T1D, a further investigation in the older adult population is warranted.
In 2021 Carlson et al.13 conducted an analysis of baseline data from the Wireless Innovations for
Seniors with Diabetes Mellitus (WISDM) study, which investigated the predictors of
hypoglycemia in adults > 60 years with T1D. Blinded CGMs were worn for 14-21 days by 203
participants. Participants spent a median time of 5.0% in hypoglycemia which is greater than the
recommended limit of 4.0%. Individuals that were rated as having reduced awareness of
hypoglycemia spent more time in very low hypoglycemia (less than 54 mg/dL; 2.7% vs 1.3%).
Nocturnal hypoglycemia was observed to be prevalent in all participants, regardless of
hypoglycemia awareness.13 Compounding the concern that older adults spend more time in
hypoglycemia are the factors which may prevent older adults from appropriately self-managing
their glucose levels, such as reduced psychomotor performance. Additionally, the
counterregulatory responses including glucagon and catecholamine secretion are reduced in older
adults.24
Another compounded concern of T1D in older adults is that of the risk of falls during an
episode of hypoglycemia. A survey of patients with T1D and greater than 55 years of age was
conducted by Shah et al.25 in 2017 and revealed that the presence of severe hypoglycemic
episodes within the past 12 months was associated with significantly increased risk of falls. One
quarter of participants required medical attention for falls within the past 12 months, and 10% of
participants experienced a fracture.25 Diabetes-associated factors besides hypoglycemia which
increase fall risk include peripheral neuropathy, vision loss, and depression.2,25 Multiple studies
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have also demonstrated that old age and longer duration of T1D increases the risk of
fractures.26,27 A 6-fold higher relative risk for hip fracture and 3-fold higher relative risk for
fracture at any site has been shown in T1D. The increased fracture risk has been attributed to
impaired bone formation due to T1D in adolescence, and is seen in deficits in bone density, size
and structure.27
Cognitive function as it relates to hypoglycemia in T1D is also compounded by agerelated decline in older adults. In regards to dementia, a bidirectional relationship between
hypoglycemia and dementia has been seen in older adults, demonstrating that memory
impairment can lead to increased hypoglycemia.6 A small-cohort longitudinal study was
completed by van Duinkerken et al in 2011 to investigate cognition over time in older T1D
patients. An initial assessment was completed 4 years prior with 36 participants with T1D and 29
controls and demonstrated decreased information processing speed in the T1D group. The
follow-up testing after 4 years showed that further decreased overall cognitive function and
information processing speed only occurred in T1D participants that had experienced severe
hypoglycemia in the time between assessments or had a history of emergency department visits
or hospitalization for hypoglycemia in their lifetimes. 28 The Study of Longevity in Diabetes
(SOLID), published in 2020 by Lacy et al.16, investigated the relationship of severe
hypoglycemia and brain health in 718 adults greater than 60 years of age with T1D. One third of
participants had experienced a severe hypoglycemic episode within the past 12 months that
required assistance from another person to resolve. Half of the participants had experienced a
severe hypoglycemic episode that resulted in an ED visit or hospitalization within their lifetimes.
A series of neurocognitive assessments in various fields were administered to assess brain health.
Recent episodes of severe hypoglycemia were linked to lower performance in global cognition,
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language, executive function and episodic memory. Lifetime episodes requiring were linked with
lower executive function scores. Analyses showed that the effect of recent severe hypoglycemia
was significant and independent of the effect of lifetime severe hypoglycemia.16 This study
supports the hypothesis that the brain is more susceptible to hypoglycemic insults during late
adulthood, compared to middle age.29 Age-related changes thought to contribute to this
susceptibility include reduced brain volume and white matter integrity.21
Mental Health Concerns in Diabetes Management
A chronic disease such as T1D has many social, emotional, and physical burdens that can
also affect the mental health of individuals. The relationship between mental health and glycemic
control must also be considered. Adults with T1D have two- to three-fold higher rates of
depression than the general population.30 Given the complex self-care requirements of those with
T1D, there is a greater psychological burden on these individuals. This has been considered as a
possible contribution to the higher rates of depression in this population.31 In a survey of adults
with T1D, elevated diabetes-related distress, elevated depressive symptoms, and high HbA1c
levels were all strongly correlated.32 In those without a diagnosis of depression, the stress
associated with maintaining adequate glucose control can still greatly affect quality of life. A
cross-sectional study in Norway including 319 adults with T1D used a series of standardized
questionnaires to assess stress, emotion, and diabetes management. Responses were analyzed in
combination with HbA1c levels of participants. Diabetes-related distress was associated with an
increase in HbA1c of 0.2% to 0.3%. When specifically evaluating regimen-related distress, an
increase of 0.6% was seen.33 Responses to scales for depression and anxiety were not
significantly associated with changes in HbA1c in this study,33 showing that the negative effects
of diabetes-related distress were independent of other existing mental health disorders.
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Regardless of the presence of microvascular and macrovascular complications of diabetes, high
HbA1c levels are associated with poorer quality of life. In Sweden, a survey of adults with T1D
and T2D was done to measure health-related quality of life (HRQOL). When controlling for
demographics and diabetes complications, significant decreases in multiple domains of HRQOL
were seen in those with HbA1c greater than 8.6%.34 In addition to high HbA1c levels, longer
duration of T1D is significantly associated with worse HRQOL.35 A study by Hessler et al.36
differed from others in that it included assessments both at baseline and at nine months. At both
time points, high diabetes-related distress was associated with higher HbA1c among adults with
T1D. However, if there was a decrease in diabetes-related distress at the nine-month follow-up,
then this was significantly associated with a simultaneous decrease in HbA1c.36
Challenges associated with mental health are also seen to impact older adults with
diabetes. Chronic physical illness is a risk factor for developing depression in those over the age
of 65. Prevalence of depression is 5-10% in older adults, and this rises to 12-18% in those with
diabetes.37 As part of the Diabetes and Aging Study of Health, telephone interviews were done to
assess factors affecting depressive symptoms in older adults with diabetes. Participants over 65
years of age were interviewed, and lower cognitive function and higher levels of diabetes-related
distress were both significantly associated with an increase in depressive symptoms.38 Another
longitudinal study followed adults over 50 years of age with T1D over a 20-year period to assess
complications over the lifespan. Twenty percent of participants were diagnosed with depression
at baseline, and rates increased over the span of the study. Severe hyperglycemic and
hypoglycemic events resulting in hospital admission or emergency care occurred twice as often
in those with depression. Conversely, an episode of severe hyperglycemia was associated with a
doubled risk of developing depression, and an episode of severe hypoglycemia was associated
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with a 75% increased risk of a new depression diagnosis.30 This bidirectional relationship
between severe glycemic events and depression highlights the importance of optimizing glucose
control.
Glucose Monitoring Modalities
Self-monitoring of blood glucose (SMBG) with a glucometer and finger-sticks has been
the standard of care for several decades. The method involves sticking the finger with a
disposable lancet and placing the resultant drop of blood onto a one-time use test strip that has
been inserted into the glucometer. The glucometer then displays the plasma glucose
concentration. It is a well-studied system and has been evaluated for accuracy. Studies have
shown that if it is used between 6 and 10 times per day, then significant reduction in HbA1c can
be achieved.8,9 While this frequent use would be more ideal, the reality is that many T1D are
unable to perform checks that often. Checking blood glucose with the finger-stick method
produces a potential for biohazards that may not be welcome in all settings. Users are also
limited by the need to access multiple supplies. Some older adults have also reported specific
limitations in their ability to obtain enough finger-stick blood to use SMBG due to comorbidities
including circulatory disorders, neuropathy, and arthritis.39 SMBG also has the negative effect of
causing pain. In Japan, a cross-sectional study was completed to assess patient attitudes
surrounding blood glucose monitoring. Participants included 517 adults with T1D and 1648 with
T2D that used SMBG for at least three months. Multiple questionnaires were included to assess
mood status, diabetes therapy related quality of life, and perceptions of SMBG. A large fraction
of participants reported pain associated with SMBG, 46.4% of T1D and 37.5% of T2D. Those
that reported pain were then more likely to exhibit additional negative characteristics. Mood and
HRQOL were rated more poorly, and HbA1c was higher in this group. Additionally, blood
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glucose monitoring was seen as less important by those with pain than those without pain.40 Due
to the inconvenience and negative associations with SMBG, alternative glucose monitoring
methods have been developed.
Continuous glucose monitoring (CGM) differs from SMBG in that it doesn’t directly
measure blood glucose and allows the reading of glucose concentration and trends as it
continuously changes throughout the day. A sensor device is placed on the body, and a filament
inserted in the skin measures glucose concentration in the interstitial fluid. Readings are
available to view on a receiver or smartphone. Two types of CGM are available for use in T1D:
real-time CGM (rtCGM) and flash glucose monitoring (FGM).
rtCGM uses a sensor that is placed on the abdomen or back of the upper arm and must be
replaced every 10 days. The sensor measures the interstitial glucose concentration every 5
minutes and automatically transmits the reading to the receiver or smartphone. Because
measurements are sent continuously, individuals can set their own high and low glucose
thresholds, and an alarm will sound if the thresholds are crossed.41 FGM sensors may only be
placed on the back of the upper arm and differ from rtCGM in that a manual scan of the sensor
with a receiver or smartphone is required to display the data. For this reason, the alarm functions
are not available on FGM. Scans only take 1 second to complete and should be done at least once
every 8 hours to ensure complete storage and transmission of data points.42 Transmitters may be
scanned more often than every 8 hours, and increased frequency of scans has been associated
with lower HbA1c levels.43 Despite the lack of alarm feature on FGM, the devices are still used
commonly because they are a lower cost alternative to rtCGM.44 Regarding accessibility,
Medicare began covering both types of CGM in 2017 for eligible persons.13
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Shared characteristics include the accuracy and types of data that can be obtained from
the device. Studies have shown that CGM devices have equivalent or greater accuracy in
tracking hyperglycemia and hypoglycemia compared to SMBG, and duration of hypoglycemic
episodes decrease in both.14,45 Earlier iterations required the use of SMBG for dosing insulin and
calibrating the devices. As of 2016, Dexcom G5, a rtCGM, was approved by the FDA to use
without adjunctive SMBG. The Abbott Freestyle Libre, a FGM, was approved to use
independently in 2014.14 Both devices also provide predictive indicator arrows based on the
trends in previous readings to inform the user if they are approaching hypoglycemic or
hyperglycemic thresholds.8 Users can then adjust carbohydrate intake or insulin bolus doses to
remain in a euglycemic range. Long-term trend data is available with FGM and rtCGM. Up to 90
days of data can be stored on the receiver, or more if using a smartphone application. Extended
trends over time can then be downloaded and assessed by an endocrinologist to inform treatment
decisions as an adjunct to HbA1c. Available data includes the fraction of time in range (TIR,
greater than 70 mg/dL and less than 180 mg/dL), time below range (TBR, less than 70 mg/dL),
and time above range (TAR, greater than 180 mg/dL). Increased fractions of TIR has been linked
to improvements in microvascular and macrovascular complications of diabetes.46–48 CGMs can
also calculate a coefficient of variation (CV) to measure glycemic variability, something that
cannot be assessed by HbA1c alone. A study including 130 adults greater than 65 years of age
with T1D showed that those with high (greater than 36%) or low (less than 36%) CV could have
the same HbA1c, but those with a high CV spent more time in hypoglycemia.49
Comparative Effects of Glucose Monitoring Technology
rtCGM vs SMBG
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Many studies have been done to analyze the difference between T1D management with
rtCGM and SMBG. An early meta-analysis done in 2012 by Floyd et al.50 included 14
randomized control trials (RCT) comparing the two modalities. The analysis revealed that across
all studies, if rtCGM was used for at least 8 weeks, significantly greater reductions in HbA1c and
time spent in hypoglycemia from baseline in the rtCGM groups were observed, though no
significant changes were seen in hypoglycemia frequency.50 Later studies were done over longer
durations to evaluate for long-term effects of rtCGM use. The Comparison of Sensory
Augmented Insulin Regimens (COMISAIR) study by Šoupal et al.17 in 2016 was conducted with
adult participants with T1D to evaluate the effects of sensor-augmented insulin regimens (SAIR).
Though not randomized, participants were divided into 4 groups utilizing different treatment
modalities for glucose monitoring and insulin administration. The SAIR groups included rtCGM
used with multiple daily injection (MDI) and continuous subcutaneous insulin infusion (CSII,
insulin pump). The other groups used SMBG with MDI and SMBG with CSII.17,51 Results after
1 year support the findings of the earlier meta-analysis in that the rtCGM groups showed
significantly lower HbA1c levels than SMBG with MDI group after only 3 months of treatment.
As the study continued, the difference in HbA1c between the rtCGM groups and SMBG with
CSII group became significant after 9 months. After 1 year, rtCGM groups also showed
decreased average glucose values, time spent in hypoglycemia, and glycemic variability when
compared to their baseline.17 After 3 years, the improvements in glycemic control were still
apparent, and decreases in TBR was only seen in the rtCGM groups.51
In 2017 Beck et al.11 published results from the Multiple Daily Injections and Continuous
Glucose Monitoring in Diabetes (DIAMOND) RCT. This trial included 158 participants with
T1D from the United States and was conducted over a span of 6 months. Participants were
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divided to rtCGM and SMBG groups, all using MDI insulin regimens. Significant differences in
HbA1c were seen after 12 weeks and were maintained at the end of the 6 months. Mean HbA1c
reduction was 1.0% in the rtCGM group, and 0.4% in the SMBG group. The rtCGM group also
spent less time in hypoglycemia than the SMBG group (43 min/d vs 80 min/d). According to
qualitative surveys administered in the study, participants who used the CGM rated it highly on
user satisfaction.11 Ruedy et al.52 expanded on the DIAMOND trial results by including data
from participants in Canada and focusing on subjects greater than 60 years of age. The subgroup
again showed greater decrease in HbA1c and high rates of user satisfaction.52 A later analysis of
the DIAMOND study data by Oliver et al.10 in 2020 revealed that rtCGM use altered the
historical inverse relationship between HbA1c and time spent in hypoglycemia. Findings from
earlier studies showed that lower mean glucose levels or HbA1c were associated with more time
spent in hypoglycemia.22 The new data showed that rtCGM users were able to achieve a lower
HbA1c while still spending less time in hypoglycemia when compared to SMBG users.10
The Continuous Glucose Monitoring vs Conventional Therapy for Glycemic Control in
Adults With Type 1 Diabetes Treated With Multiple Daily Insulin Injections (GOLD) RCT
conducted in Sweden in 2018 was designed similarly to the DIAMOND study but also included
a 17-week washout period where users in the rtCGM group were returned to SMBG. Like the
DIAMOND trial, adults with T1D were shown to have reduced time in hypoglycemia, both in
daytime and nocturnal hours, when using rtCGM.22 However, during the washout period, time in
hypoglycemia returned to pre-rtCGM levels, reinforcing the association between rtCGM use and
a reduction in duration of hypoglycemia. Users also rated their hypoglycemia management
confidence at the end of the treatment arm. Confidence after using rtCGM was higher than after
SMBG treatment.53,54
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Additional studies were done to evaluate time spent in hypoglycemia. The data analysis
by Avari et al.55 for the Randomized Trial Comparing Continuous Glucose Monitoring With and
Without Routine Blood Glucose Monitoring in Adults With Type 1 Diabetes (REPLACE-BG)56
used rtCGM and SMBG data from 226 participants with T1D. rtCGM users were calculated to
spend a significantly greater percentage of time in range (TIR) and lower percentage of time
below range (TBR) when compared to SMBG users.55 A much smaller prospective cohort study
containing only 11 participants with T1D and impaired hypoglycemia awareness was published
by Rickels et al.18 in 2018. The results were in line with previous studies and participants showed
a reduction in time in hypoglycemia compared to their baseline.18
The Reimbursement Study of Continuous Glucose Monitoring in Belgium (RESCUE)
trial assessed both clinical and qualitative outcomes after one year of CGM use in patients using
an insulin pump. Similar to studies using MDI regimens,11,18,22,55 HbA1c and time spent in
hypoglycemia were seen to decrease significantly from baseline. Hypoglycemia-related
hospitalizations and days of missed work due to diabetes-related issues also decreased between
the year prior and the duration of the study.57 Quality of life assessments showed improvements
in diabetes-related worry, general health, and social functioning. The greatest improvements
were noted in individuals that had poorly managed hypoglycemia at the start of the study.57
More focused qualitative studies were done to assess the patient satisfaction when
transitioning from SMBG to CGM in patients using insulin pumps. A study by Rubin and
Peyrot58 in 2009 consisted of a survey given to 311 adults with T1D that used either a
rtCGM/CSII system or SMBG with CSII. Participants using rtCGM rated it higher in overall
satisfaction and glucose control and were more likely to recommend their monitoring system
than those using SMBG.58 HRQOL and convenience were not significantly different between
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groups in this study. 58 In 2014, Hommel et al.59 analyzed data from the SWITCH (sensing with
insulin pump therapy to control HbA1c) study. All participants in this study went through phases
with and without linking the CGM to their insulin pumps. Treatment satisfaction was again
significantly higher when using the CGM, though HRQOL was not significantly impacted.59 In
contrast to the earlier study,58 convenience was rated higher following CGM use.59
In a more recent study, interviews were conducted among 24 adults and parents of
children with T1D that had been using a CGM for at least four weeks. Participants stated several
benefits to the device. Using a CGM made it easier and faster to check glucose levels and was
compared to checking the time on a watch. Users found the trending arrows to be accurate
predictors of their glucose patterns and to be the most helpful feature in making decisions
surrounding food intake, insulin administration, and activities such as exercise or driving. The
alarm function for severe high or low glucose levels also gave users a sense of security and
reduced anxiety.60
In 2020 the first large RCT involving only older adults with T1D was published by
Pratley et al.61 The WISDM study included 203 adults greater than 60 years of age using either
MDI or CSII insulin regimens. The study focused on the effect of rtCGM on time in
hypoglycemia, and results showed the difference between rtCGM and SMBG groups to be
significant, with effects seen after one month and remaining through the six months of the trial.
The rtCGM group reduced TBR from 5.1% to 2.7%, while the SMBG TBR remained constant
(4.7% to 4.9%). The average decrease in HbA1c was also greater in the rtCGM group.61 Based
on the results of the WISDM trial, the ADA adopted a new recommendation in 2021 that
providers should consider CGM use in older adults with T1D.62
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Litchman et al.24 and Polonsky et al.63 conducted additional qualitative studies with
individuals with T1D or insulin dependent T2D greater than 65 years of age. Current rtCGM
users and SMBG users were both included.24,63 Respondents noted that they were better able to
self-treat hypoglycemia using the visible trends and alarms found on the rtCGM, and felt they
could effectively avoid severe hypoglycemia. rtCGM users in both studies experienced fewer
severe hypoglycemic episodes and related falls.24,63 An improved sense of safety allowed
individuals to drive, exercise, and travel with less worry.24 Assessments of hypoglycemia fear
and diabetes-related distress were scored lower in rtCGM users.63
FGM vs SMBG
The Novel Glucose-Sensing Technology and Hypoglycemia in Type 1 Diabetes: a
Multicentre, Non-masked, Randomized Controlled Trial (IMPACT) by Oskarsson et al.64 was
done to compare FGM with SMBG across Europe over a 6-month period. 167 participants with
well-controlled (HbA1c < 7.5%) T1D were included in the study, as the primary goal was to
assess change in hypoglycemia rates. After a 2-week blinded run-in stage to establish baseline
hypoglycemia rates, participants were divided randomly into FGM and SMBG groups. As with
rtCGM, FGM users rated their satisfaction with the device highly. Time in hypoglycemia
decreased by 46% in the FGM group over the 6-month trial, from 3.44 hr/d to 1.86 hr/d. No
change in HbA1c was seen in this study.64
Tyndall et al.43 produced a prospective observational study with HbA1c change as the
primary investigation. 900 participants were given FGM devices, and 518 participants used
SMBG for the control group. In contrast to the IMPACT trial, participants of all HbA1c ranges
were included in the study, and reductions > 0.5% were seen in 48.1% of FGM users. The
greatest change from baseline was seen in users with a HbA1c >9.0%. No significant change in
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HbA1c was seen in the control group. A secondary finding was a significant decrease in the rate
of DKA admissions in the FGM group.43
In 2021, Nathanson et al.44 published the results of a 2-year observational cohort study of
FGM and SMBG users with T1D. Data was obtained from the Swedish National Diabetes
Registry. The FGM group consisted on individuals that were newly started on FGM and
remained on the system for 2 consecutive years. SMBG users from the same date range were
used as controls. The study showed that HbA1c decreased gradually in both FGM and SMBG
groups, but the decrease was significantly greater in the FGM group. Like the Tyndall et al.43
study, the greatest change in HbA1c occurred in those who started with higher baseline values (>
8.5%). Unlike the previous studies in FGM, a decreased risk of severe hypoglycemia was seen
with FGM use. The treatment group had a 21% lower risk of experiencing 1 or more severe
hypoglycemic episodes when compared to the control group.44
Another prospective observational study was completed by Fokkert et al.65 to assess
glycemic and qualitative outcomes after one year of FGM use. The flash monitor registry in the
Netherlands (FLARE-NL) included 1365 adults with T1D or T2D that relied on insulin
administration. Baseline data from the prior year was compared with values measured after using
FGM. The study again revealed a decrease in HbA1c and hypoglycemic events with FGM use.
Additionally, diabetes-related hospital admissions and work-absenteeism decreased significantly.
Qualitative observations included decreased perception of disease burden and improved
HRQOL. Participants reported better understanding of their glucose variations and greater
confidence in self-treating glucose fluctuations. Family and housemates of participants also
worried less about the participants’ diabetes following FGM use.65
rtCGM vs FGM
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As rtCGM and FGM have both shown to reduce hypoglycemia duration, a direct
comparison study was done to assess which CGM type is optimal for adults with T1D that have
an impaired awareness of hypoglycemia. The Randomized Controlled Pilot Study of CGM and
FGM in People with T1D and Impaired Awareness of Hypoglycemia (I-HART CGM) by Reddy
et al.12 was a shorter trial at only 16 weeks in length. The first phase included 40 adults with T1D
and impaired awareness of hypoglycemia, as rated by a self-report questionnaire or a history of a
recent severe hypoglycemia episode. Participants were randomly divided into rtCGM or FGM
groups for 8 weeks. Both groups saw an increased TIR from their baseline, but only the rtCGM
group showed significant decrease in time in hypoglycemia (4.5% to 2.4%). Fear of
hypoglycemia was also rated lower in the rtCGM group.12 An extension phase continued the
study for another 8 weeks, this time assessing if improvements in glycemic outcomes were seen
when switching from FGM to rtCGM. All participants used rtCGM for the next 8 weeks, and the
participants previously using FGM showed significantly reduced time in hypoglycemia and
increased TIR after switching to rtCGM. No significant changes were seen in HbA1c in either
the initial or extension phases of the study.66
Methods
The articles used in this review were found in a literature search of the PubMed database
and Google Scholar between June 1 and July 1, 2021. The search was filtered to include peerreviewed articles with subjects “middle aged +, age 45+ years” and publication date within the
last 10 years, with the majority being published within the past 5 years. Search terms included
“type 1 diabetes”, “older adult”, “continuous glucose monitoring”, “hemoglobin A1c”,
“hypoglycemia”, “risks”, “polypharmacy”, “mental health”, “quality of life” and “falls”.
Reference lists of articles were further reviewed to identify additional relevant studies.
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Discussion
The complex nature of T1D necessitates a thorough evaluation of optimal treatment
strategies, especially regarding the additional needs of older adults. In all individuals, the clinical
goals of care include lowering HbA1c and minimizing the time spent in hypoglycemia.7 With
close control of blood glucose, HbA1c can be lowered to ideal levels of less than 7.0%.9,11,51
Without control, rates of long-term diabetic complications including neuropathy and
nephropathy are higher, as well as rates of DKA and severe hypoglycemia.5 Frequent or severe
hypoglycemia has additional negative effects. Cardiac effects include tachycardia, lengthening of
the QTc interval, and possible arrhythmias, which may be fatal. Hypoglycemia impacts cognition
through impaired memory and decreased global cognitive function, and repeated events can lead
to worsening mental efficiency.2,6 Older adults have more risk associated with the cognitive
deficits. In addition to these acute effects, the risk for dementia is higher in this population. The
combination of poor coordination and higher rates of osteoporosis increases the likelihood of a
dangerous fall and serious fracture occurring during an episode of hypoglycemia.6,31 Not only do
older adults with T1D have more risk associated with severe hypoglycemia, but they are more
likely to experience it than younger individuals. As prevalence of dementia and depression
increase in this age group, so do the rates of severe hypoglycemic episodes.6,31 Altered
nutritional intake may also couple with the decreased rates of insulin clearance to increase the
chances of becoming hypoglycemic.6 With increased prevalence of hypoglycemia and its
associated dangers, controlling glycemic variability is of great importance among older adults
with T1D.
Blood glucose monitoring is essential to lower HbA1c and protect against hypoglycemia.
For many years, SMBG has been the standard of care for those with T1D. If it is done frequently
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enough and individuals are able to recognize and interpret trends appropriately, then good
outcomes may be achieved.8,9 However, proper and frequent use of SMBG is limited by several
factors, several of which disproportionately affect older adults. Poor circulation, dehydration,
and anemia caused by poor nutrition or chronic disease can impair an individual’s ability to
obtain enough blood with finger sticks for accurate readings. Higher rates of neuropathy and
arthritis39 add to the pain that is already experienced by many that use SMBG, further
disincentivizing the practice.40 Arthritis and vision decline also increase the difficulty of using
SMBG, as fine motor skills are required for the multistep process.39 Given these limitations, it is
not surprising that this is no longer the best option for monitoring glucose levels.
Within the past decade, studies have shown that CGM technology consistently
outperforms SMBG in several categories. The foremost metric for monitoring treatment efficacy
in diabetes is HbA1c. Those using SMBG must do six to ten checks every day to achieve and
maintain modest reduction in HbA1c, but most individuals with T1D do an average of four to
five checks daily.8,9 Those that use CGM are more likely to reduce their HbA1c levels, and in
direct comparison trials, greater reductions are seen with CGM.10–12,17,43,44,50,51,65 Given the
relationship between HbA1c and complications of diabetes, the overwhelming amount of
evidence favoring CGM makes it clear that the recommendation for all persons with T1D should
be to use a CGM. Even for older adults, any efforts that can be made to slow the progression of
cardiovascular, cerebrovascular, or renal disease should be considered.
A more immediate concern for older adults with T1D is time spent in hypoglycemia.
Again, studies have demonstrated that CGM is more effective than SMBG at reducing frequency
of hypoglycemic events and total time below range.10,11,17,18,22,51,53,55 A large disadvantage of
SMBG is that it only provides point-in-time glucose values. If a person does not check their

CGM in Older Adults with T1D, 25
glucose, they may not realize that they are in hypoglycemia. Mild to moderate hypoglycemia
may be asymptomatic for many, including older adults that are less likely to mount the
compensatory catecholamine response. As the frequency of hypoglycemic events increases, the
symptomatic threshold can also shift, creating impaired awareness of hypoglycemia which only
serves to further this cycle.6,18,19 Because CGM provides the user with glucose levels at regular
intervals throughout the day, both the patient and their provider are made aware of any
hypoglycemic episodes that occur, whether symptoms are present or not. The CGM devices also
display arrows to show which direction glucose levels are currently trending, so users are able to
predict and prevent hypoglycemic episodes before they occur.60
Though the predictive trend arrows are available on all CGM devices, the rtCGM holds a
major advantage over FGM. Whereas FGM requires the individual to scan the sensor with
receiver every eight hours, rtCGM automatically sends all data to the receiver.41,42 Real-time
CGM also has the added function of alarms to signal departure from optimal glucose ranges. For
those at risk for frequent or severe hypoglycemia, users may set their rtCGM to alert them if their
glucose goes below a self-determined threshold. Many individuals with T1D have found that this
function causes the greatest reduction in diabetes-related anxiety.60 From a clinical standpoint,
the rtCGM is shown to reduce time in hypoglycemia and hyperglycemia more than FGM. Both
serve to reduce HbA1c, though comparative studies have not shown the difference in reduction
between the two systems to be significant. However, the increased TIR with rtCGM is
statistically significant.66 Further, this factor is of more importance to older adults with T1D, in
whom hypoglycemia is the greatest concern. The rtCGM is preferrable for older adults in other
ways, beyond clinical endpoints. The automatic transfer of data without the need to scan the
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sensor is easier for those that may have impaired memory function. For those that have impaired
awareness of hypoglycemia, the alarm functions can prevent critically low glucose levels.
Several benefits to quality of life are possible with CGM use. Diabetes-related distress is
associated with poorer HRQOL and higher HbA1c.36 Many factors can be causes of distress
including the presence of complications, frequency of severe hypoglycemic events, anxiety
surrounding the disease, impacts on occupational and social activities, and the time and effort
required to maintain adequate glucose levels. Specifically, regimen-related stress was
demonstrated to have a greatest impact.33 Maintenance regimens for those with T1D include
appropriate insulin administration, dietary choices, and blood glucose monitoring. By switching
individuals from SMBG to CGM, the stress associated with glucose monitoring may be reduced.
Users report CGM to be easier and faster than SMBG, with less disruption to their daily lives.60
Because the CGM is used continuously for 10 to 14 days, patients do not have a need to bring
glucose testing supplies with them at all times. Considering this and the improvements in
glycemic control, it is understandable that qualitative studies of CGM users have demonstrated
high treatment satisfaction and improved HRQOL.57–60 For those with T1D and a concurrent
depressive disorder, this reduction in regimen-related stress would also possibly result in fewer
depressive symptoms. Importantly for older adults, this would further reduce risks of severe
hyperglycemic and severe hypoglycemic episodes.30
Conclusion
In light of the advantages of CGM, it is no surprise that the ADA updated
recommendations in 2021 to include CGM as the preferred method of glucose monitoring for
older adults.62 However, this recommendation was based primarily on the publication of the
WISDM study, which demonstrated the ability of daily CGM use to reduce hypoglycemia in this
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population.61 While this endpoint has the greatest immediate impact on the health of many older
adults with T1D, there is potential for further study in other areas. Quality of life assessments
were completed for CGM users of all ages, but no specific studies were done among older adults,
and the broad range of lifestyle differences in those over 65 years of age was not explored. All
studies were done among community-dwelling older adults, excluding those residing in assisted
living or skilled nursing facilities. Further studies should be done to explore CGM use in these
settings. For parents and caregivers of children with T1D, CGM use was associated with
decreased diabetes-related distress and improved HRQOL.60 At this time, no similar study has
been done with caregivers of older adults with either T1D or T2D.
Despite the many known advantages of CGM, SMBG continues to be the standard of
care for those with T1D. The use of CGM is increasing among all individuals with T1D, but the
slowest increase is among adults over 50 years of age. SMBG use is more than twice as common
as CGM use in this age group.67 It’s possible that many older adults are simply resistant to
change after having the same treatment method for many years. Though treatment satisfaction is
high among CGM users,58,59 there may be apprehension due to the learning curve associated with
all new technologies. Usability among older adults should be studied to evaluate how to optimize
CGM systems for use by this population. In the past, cost was a large factor in decreasing use.
However, in 2017 Medicare began covering CGMs, improving access for many older adults with
T1D. As access has increased and many benefits are possible, including reducing hypoglycemia,
CGM use should be standard of care in all older adults with T1D, and providers should advocate
for their use in all who are willing.

CGM in Older Adults with T1D, 28
References
1.
Statistics About Diabetes ADA Web Site. Accessed July 2, 2021.
https://www.diabetes.org/resources/statistics/statistics-about-diabetes
2.

Dhaliwal R, Weinstock RS. In Brief Management of Type 1 Diabetes in Older Adults.
Diabetes Spectr. 2014;27(1):9-20.

3.

Mobasseri M, Shirmohammadi M, Amiri T, Vahed N, Hosseini Fard H, Ghojazadeh M.
Prevalence and incidence of type 1 diabetes in the world: a systematic review and metaanalysis. Heal Promot Perspect. 2020;10(2):98-115. doi:10.34172/hpp.2020.18

4.

Dimeglio LA, Evans-Molina C, Oram RA. Type 1 diabetes. Lancet.
2018;391(10138):2449-2462. doi:10.1016/S0140-6736(18)31320-5

5.

Pettus JH, Zhou FL, Shepherd L, et al. Incidences of severe hypoglycemia and diabetic
ketoacidosis and prevalence of microvascular complications stratified by age and
glycemic control in U.S. Adult Patients with Type 1 Diabetes: A real-world study.
Diabetes Care. 2019;42(12):2220-2227. doi:10.2337/dc19-0830

6.

Amiel SA. The consequences of hypoglycaemia. Diabetologia. 2021;64:963-970.
doi:10.1007/s00125-020-05366-3

7.

Glycemic targets: Standards of medical care in diabetes−2021. Diabetes Care.
2021;44(Supplement 1):S73-S84. doi:10.2337/dc21-S006

8.

Boscari F, Avogaro A. Current treatment options and challenges in patients with Type 1
diabetes: Pharmacological, technical advances and future perspectives. Rev Endocr Metab
Disord. 2021;22:217-240. doi:10.1007/s11154-021-09635-3

9.

Miller KM, Beck RW, Bergenstal RM, et al. Evidence of a strong association between
frequency of self-monitoringof blood glucose and hemoglobin A1c levels in T1D
exchange clinic registry participants. Diabetes Care. 2013;36:2009-2014.
doi:10.2337/dc12-1770

10.

Oliver N, Gimenez M, Calhoun P, et al. Continuous Glucose Monitoring in People With
Type 1 Diabetes on Multiple-Dose Injection Therapy: The Relationship Between
Glycemic Control and Hypoglycemia. Diabetes Care. 2020;43:53-58. doi:10.2337/dc190977

11.

Beck RW, Riddlesworth T, Ruedy K, et al. Effect of continuous glucose monitoring on
glycemic control in adults with type 1 diabetes using insulin injections the diamond
randomized clinical trial. J Am Med Assoc. 2017;317(4):371-378.
doi:10.1001/jama.2016.19975

12.

Reddy M, Jugnee N, El Laboudi A, Spanudakis E, Anantharaja S, Oliver N. A randomized
controlled pilot study of continuous glucose monitoring and flash glucose monitoring in
people with Type 1 diabetes and impaired awareness of hypoglycaemia. Diabet Med.
2018;35(4):483-490. doi:10.1111/dme.13561

13.

Carlson AL, Kanapka LG, Miller KM, et al. Hypoglycemia and Glycemic Control in
Older Adults With Type 1 Diabetes: Baseline Results From the WISDM Study. J Diabetes

CGM in Older Adults with T1D, 29
Sci Technol. 2021;15(3):582-592. doi:10.1177/1932296819894974
14.

Bailey TS. Clinical implications of accuracy measurements of continuous glucose sensors.
Diabetes Technol Ther. 2017;19(S2):S51-S54. doi:10.1089/dia.2017.0050

15.

Beck RW, Conner CG, Mullen DM, Wesley DM, Bergenstal RM. The Fallacy of
Average: How Using HbA 1c Alone to Assess Glycemic Control Can Be Misleading.
Diabetes Care. 2017;40:994-999. doi:10.2337/dc17-0636

16.

Lacy ME, Gilsanz P, Eng C, Beeri MS, Karter AJ, Whitmer RA. Severe hypoglycemia
and cognitive function in older adults with type 1 diabetes: The Study of Longevity in
Diabetes (SOLID). Diabetes Care. 2020;43:541-548. doi:10.2337/dc19-0906

17.

Šoupal J, Petruželková L, Flekač M, et al. Comparison of Different Treatment Modalities
for Type 1 Diabetes, Including Sensor-Augmented Insulin Regimens, in 52 Weeks of
Follow-Up: A COMISAIR Study. Diabetes Technol Ther. 2016;18(9):532-538.
doi:10.1089/dia.2016.0171

18.

Rickels MR, Peleckis AJ, Dalton-Bakes C, et al. Continuous glucose monitoring for
hypoglycemia avoidance and glucose counterregulation in long-standing type 1 diabetes. J
Clin Endocrinol Metab. 2018;103(1):105-114. doi:10.1210/jc.2017-01516

19.

Lin YK, Fisher SJ, Pop-Busui R. Hypoglycemia unawareness and autonomic dysfunction
in diabetes: Lessons learned and roles of diabetes technologies. J Diabetes Investig.
2020;11(6):1388-1402. doi:10.1111/jdi.13290

20.

Martyn-Nemeth P, Phillips SA, Mihailescu D, et al. Poor sleep quality is associated with
nocturnal glycaemic variability and fear of hypoglycaemia in adults with type 1 diabetes. J
Adv Nurs. 2018;74(10):2373-2380. doi:10.1111/jan.13765

21.

Ryan CM, Klein BEK, Lee KE, Cruickshanks KJ, Klein R. Associations between Recent
Severe Hypoglycemia, Retinal Vessel Diameters, and Cognition in Adults with Type 1
Diabetes. J Diabetes Complicat. 2016;30(8):1513-1518.
doi:10.1016/j.jdiacomp.2016.08.010

22.

Ahmadi SS, Westman K, Pivodic A, et al. The association between HbA1c and time in
hypoglycemia during cgm and self-monitoring of blood glucose in people with type 1
diabetes and multiple daily insulin injections: A randomized clinical trial (GOLD-4).
Diabetes Care. 2020;43:2017-2024. doi:10.2337/dc19-2606

23.

McCoy RG, Lipska KJ, Van Houten HK, Shah ND. Association of Cumulative
Multimorbidity, Glycemic Control, and Medication Use with Hypoglycemia-Related
Emergency Department Visits and Hospitalizations among Adults with Diabetes. JAMA
Netw Open. 2020;3(1):1-16. doi:10.1001/jamanetworkopen.2019.19099

24.

Litchman ML, Allen NA. Real-Time Continuous Glucose Monitoring Facilitates Feelings
of Safety in Older Adults With Type 1 Diabetes: A Qualitative Study. J Diabetes Sci
Technol. 2017;11(5):988-995. doi:10.1177/1932296817702657

25.

Shah VN, Wu M, Foster N, Dhaliwal R, Al Mukaddam M. Severe hypoglycemia is
associated with high risk for falls in adults with type 1 diabetes. Arch Osteoporos.
2018;13:66. doi:10.1007/s11657-018-0475-z

CGM in Older Adults with T1D, 30
26.

Dhaliwal R, Foster NC, Boyle C, et al. Determinants of fracture in adults with type 1
diabetes in the USA: Results from the T1D Exchange Clinic Registry. J Diabetes
Complications. 2018;32:1006-1011. doi:10.1016/j.jdiacomp.2018.08.016

27.

Weber DR, Schwartz G. Epidemiology of Skeletal Health in Type 1 Diabetes. Curr
Osteoporos Rep. 2016;14:327-336. doi:10.1007/s11914-016-0333-0

28.

van Duinkerken E, Brands AM, van den Berg E, Henselmans JM, Hoogma RP, Biessels
GJ. Cognition in Older Patients with Type 1 Diabetes Mellitus: A Longitudinal Study. J
Am Geriatr Soc. 2011;59(3):563-565.

29.

Biessels GJ, Deary IJ, Ryan CM. Cognition and diabetes: a lifespan perspective. Lancet
Neurol. 2008;7(2):184-190. doi:10.1016/S1474-4422(08)70021-8

30.

Gilsanz P, Karter AJ, Beeri MS, Quesenberry CP, Whitmer RA. The Bidirectional
Association Between Depression and Severe Hypoglycemic and Hyperglycemic Events in
Type 1 Diabetes. Diabetes Care. 2018;41:446-452. doi:10.2337/dc17-1566

31.

Gilsanz P, Beeri MS, Karter AJ, Quesenberry CP, Adams AS, Whitmer RA. Depression in
Type 1 Diabetes and Risk of Dementia. Aging Ment Heal. 2019;23(7):880-886.
doi:10.1080/13607863.2018.1455167

32.

Mccarthy MM, Gholson G, Grey M, Goodrich A. Diabetes Distress, Depressive
Symptoms and Cardiovascular Health in Adults with Type 1 Diabetes. Nurs Res.
2019;68(6):445-452. doi:10.1097/NNR.0000000000000387

33.

Strandberg RB, Graue M, Wentzel-Larsen T, Peyrot M, Rokne B. Relationships of
diabetes-specific emotional distress, depression, anxiety, and overall well-being with
HbA1c in adult persons with type 1 diabetes. J Psychosom Res. 2014;77:174-179.
doi:10.1016

34.

Engström MS, Leksell J, Johansson U-B, et al. Health-related quality of life and
glycaemic control among adults with type 1 and type 2 diabetes-a nationwide crosssectional study. Health Qual Life Outcomes. 2019;17:141. doi:10.1186/s12955-019-1212z

35.

Wasif Gillani S, Altaf Ansari I, Zaghloul HA, et al. Women with Type 1 Diabetes
Mellitus: Effect of Disease and Psychosocial-Related Correlates on Health-Related
Quality of Life. J Diabetes Res. 2018;2018:4079087. doi:10.1155/2018/4079087

36.

Hessler DM, Fisher L, Polonsky WH, et al. Diabetes distress is linked with worsening
diabetes management over time in adults with Type 1 diabetes. Diabet Med.
2017;34(9):1228-1234. doi:10.1111/dme.13381

37.

Park M, Reynolds CF. Depression among older adults with diabetes mellitus. Clin Geriatr
Med. 2015;31(1):117-137. doi:10.1016/j.cger.2014.08.022

38.

Jones LC, Clay OJ, Ovalle F, Cherrington A, Crowe M. Correlates of Depressive
Symptoms in Older Adults with Diabetes. J Diabetes Res. 2016;2016:8702730.
doi:10.1155/2016/8702730

39.

Forlenza GP, Argento NB, Laffel LM. Practical Considerations on the Use of Continuous

CGM in Older Adults with T1D, 31
Glucose Monitoring in Pediatrics and Older Adults and Nonadjunctive Use. Diabetes
Technol Ther. 2017;19(S3):S13-S20. doi:10.1089/dia.2017.0034
40.

Tanaka N, Yabe D, Murotani K, et al. Mental distress and health-related quality of life
among type 1 and type 2 diabetes patients using self-monitoring of blood glucose: A
cross-sectional questionnaire study in Japan. J Diabetes Investig. 2018;9(5):1203-1211.
doi:10.1111/jdi.12827

41.

What Is CGM? Continuous Glucose Monitoring Defined Dexcom Web Site. Accessed
July 1, 2021. https://www.dexcom.com/continuous-glucose-monitoring

42.

FreeStyle Libre 14 day System CGM Diabetes Monitor Web Site. Accessed July 1, 2021.
https://www.freestyle.abbott/us-en/products/freestyle-14-day.html

43.

Tyndall V, Stimson RH, Zammitt NN, et al. Marked improvement in HbA1c following
commencement of flash glucose monitoring in people with type 1 diabetes. Diabetologia.
2019;62:1349-1356. doi:10.1007/s00125-019-4894-1

44.

Nathanson D, Svensson AM, Miftaraj M, Franzén S, Bolinder J, Eeg-Olofsson K. Effect
of flash glucose monitoring in adults with type 1 diabetes: a nationwide, longitudinal
observational study of 14,372 flash users compared with 7691 glucose sensor naive
controls. Diabetologia. 2021;64:1595-1603. doi:10.1007/s00125-021-05437-z

45.

Lindner N, Kuwabara A, Holt T. Non-invasive and minimally invasive glucose
monitoring devices: a systematic review and meta-analysis on diagnostic accuracy of
hypoglycaemia detection. Syst Rev. 2021;10(145). doi:10.1186/s13643-021-01644-2

46.

Ranjan AG, Rosenlund S V., Hansen TW, Rossing P, Andersen S, Nørgaard K. Improved
time in range over 1 year is associated with reduced albuminuria in individuals with
sensor-augmented insulin pump– treated type 1 diabetes. Diabetes Care.
2020;43(11):2882-2885. doi:10.2337/dc20-0909

47.

Lu J, Ma X, Shen Y, et al. Time in Range Is Associated with Carotid Intima-Media
Thickness in Type 2 Diabetes. Diabetes Technol Ther. 2020;22(2):72-78.
doi:10.1089/dia.2019.0251

48.

Lu J, Ma X, Zhou J, et al. Association of time in range, as assessed by continuous glucose
monitoring, with diabetic retinopathy in type 2 diabetes. Diabetes Care.
2018;41(11):2370-2376. doi:10.2337/dc18-1131

49.

Toschi E, Slyne C, Sifre K, et al. The relationship between CGM-derived metrics, A1C,
and risk of hypoglycemia in older adults with type 1 diabetes. Diabetes Care.
2020;43(10):2349-2354. doi:10.2337/dc20-0016

50.

Floyd B, Chandra P, Hall S, et al. Comparative analysis of the efficacy of continuous
glucose monitoring and self-monitoring of blood glucose in type 1 diabetes mellitus. J
Diabetes Sci Technol. 2012;6(5):1094-1102. doi:10.1177/193229681200600513

51.

Šoupal J, Petruželkova L, Grunberger G, et al. Glycemic outcomes in adults with T1D are
impacted more by continuous glucose monitoring than by insulin delivery method: 3 years
of follow-up from the comisair study. Diabetes Care. 2020;43(1):37-43.
doi:10.2337/dc19-0888

CGM in Older Adults with T1D, 32
52.

Ruedy KJ, Parkin CG, Riddlesworth TD, Graham C. Continuous Glucose Monitoring in
Older Adults With Type 1 and Type 2 Diabetes Using Multiple Daily Injections of
Insulin: Results From the DIAMOND Trial. J Diabetes Sci Technol. 2017;11(6):11381146. doi:10.1177/1932296817704445

53.

Ólafsdóttir AF, Polonsky W, Bolinder J, et al. A Randomized Clinical Trial of the Effect
of Continuous Glucose Monitoring on Nocturnal Hypoglycemia, Daytime Hypoglycemia,
Glycemic Variability, and Hypoglycemia Confidence in Persons with Type 1 Diabetes
Treated with Multiple Daily Insulin Injections (GOLD-3). Diabetes Technol Ther.
2018;20(4):274-284. doi:10.1089/dia.2017.0363

54.

Lind M, Polonsky W, Hirsch IB, et al. Continuous glucose monitoring vs conventional
therapy for glycemic control in adults with type 1 diabetes treated with multiple daily
insulin injections: The GOLD Randomized Clinical Trial. J Am Med Assoc.
2017;317(4):379-387. doi:10.1001/JAMA.2016.19976

55.

Avari P, Uduku C, George D, Herrero P, Reddy M, Oliver N. Differences for Percentage
Times in Glycemic Range Between Continuous Glucose Monitoring and Capillary Blood
Glucose Monitoring in Adults with Type 1 Diabetes: Analysis of the REPLACE-BG
Dataset. Diabetes Technol Ther. 2020;22(3):222-227. doi:10.1089/dia.2019.0276

56.

Aleppo G, Ruedy KJ, Riddlesworth TD, et al. REPLACE-BG: A Randomized Trial
Comparing Continuous Glucose Monitoring With and Without Routine Blood Glucose
Monitoring in Adults With Well-Controlled Type 1 Diabetes. Diabetes Care.
2017;40:538-545. doi:10.2337/dc16-2482

57.

Charleer S, Mathieu C, Nobels F, et al. Effect of Continuous Glucose Monitoring on
Glycemic Control, Acute Admissions, and Quality of Life: A Real-World Study. J Clin
Endocrinol Metab. 2018;103(3):1224-1232. doi:10.1210/jc.2017-02498

58.

Rubin RR, Peyrot M, Piney E, Road H. Treatment Satisfaction and Quality of Life for an
Integrated Continuous Glucose Monitoring/Insulin Pump System Compared to SelfMonitoring Plus an Insulin Pump. J Diabetes Sci Technol. 2009;3(6).
www.journalofdst.org

59.

Hommel E, Olsen B, Battelino T, et al. Impact of continuous glucose monitoring on
quality of life, treatment satisfaction, and use of medical care resources: analyses from the
SWITCH study. Acta Diabetol. 2014;51:845-851. doi:10.1007/s00592-014-0598-7

60.

Lawton J, Blackburn M, Allen J, et al. Patients’ and caregivers’ experiences of using
continuous glucose monitoring to support diabetes self-management: qualitative study.
BMC Endocr Disord. 2018;18(12). doi:10.1186/s12902-018-0239-1

61.

Pratley RE, Kanapka LG, Rickels MR, et al. Effect of Continuous Glucose Monitoring on
Hypoglycemia in Older Adults With Type 1 Diabetes A Randomized Clinical Trial. J Am
Med Assoc. 2020;323(23):2397-2406. doi:10.1001/jama.2020.6928

62.

Summary of Revisions: Standards of Medical Care in Diabetes-2021. Diabetes Care.
2021;44(Suppl. 1):S4-S6. doi:10.2337/dc21-Srev

63.

Polonsky WH, Peters AL, Hessler D. The Impact of Real-Time Continuous Glucose

CGM in Older Adults with T1D, 33
Monitoring in Patients 65 Years and Older. J Diabetes Sci Technol. 2016;10(4):892-897.
doi:10.1177/1932296816643542
64.

Oskarsson P, Antuna R, Geelhoed-Duijvestijn P, Krӧger J, Weitgasser R, Bolinder J.
Impact of flash glucose monitoring on hypoglycaemia in adults with type 1 diabetes
managed with multiple daily injection therapy: a pre-specified subgroup analysis of the
IMPACT randomised controlled trial. Diabetologia. 2018;61:539-550.
doi:10.1007/s00125-017-4527-5

65.

Fokkert M, van Dijk P, Edens M, et al. Improved well-being and decreased disease burden
after 1-year use of flash glucose monitoring (FLARE-NL4). BMJ Open Diab Res Care.
2019;7:e000809. doi:10.1136/bmjdrc-2019-000809

66.

Reddy M, Jugnee N, Anantharaja S, Oliver N. Switching from Flash Glucose Monitoring
to Continuous Glucose Monitoring on Hypoglycemia in Adults with Type 1 Diabetes at
High Hypoglycemia Risk: The Extension Phase of the I HART CGM Study. Diabetes
Technol Ther. 2018;20(11):751-757. doi:10.1089/dia.2018.0252

67.

Foster NC, Beck RW, Miller KM, et al. State of Type 1 Diabetes Management and
Outcomes from the T1D Exchange in 2016-2018. Published online 2010.
doi:10.1089/dia.2018.0384

Augsburg University Institutional Repository Deposit Agreement
By depositing this Content (“Content”) in the Augsburg University Institutional Repository known as Idun, I agree
that I am solely responsible for any consequences of uploading this Content to Idun and making it publicly available,
and I represent and warrant that:
●

I am either the sole creator or the owner of the copyrights in the Content; or, without obtaining another’s
permission, I have the right to deposit the Content in an archive such as Idun.
● To the extent that any portions of the Content are not my own creation, they are used with the copyright
holder’s expressed permission or as permitted by law. Additionally, the Content does not infringe the
copyrights or other intellectual property rights of another, nor does the Content violate any laws or
another’s right of privacy or publicity.
● The Content contains no restricted, private, confidential, or otherwise protected data or information that
should not be publicly shared.
I understand that Augsburg University will do its best to provide perpetual access to my Content. To support these
efforts, I grant the Board of Regents of Augsburg University, through its library, the following non-exclusive,
perpetual, royalty free, worldwide rights and licenses:
●

To access, reproduce, distribute and publicly display the Content, in whole or in part, to secure, preserve
and make it publicly available
● To make derivative works based upon the Content in order to migrate to other media or formats, or to
preserve its public access.
These terms do not transfer ownership of the copyright(s) in the Content. These terms only grant to Augsburg
University the limited license outlined above.

Initial one:
___ I agree and I wish this Content to be Open Access.
___ I agree, but I wish to restrict access of this Content to the Augsburg University
network.
Work (s) to be deposited
Continuous Glucose Monitoring: Optimizing Type 1 Diabetes Managment in Older Adults
Title: _______________________________________________________
Alyssa Clements
Author(s) of Work(s): ___________________________________________
Alyssa Clements
Depositor’s Name (Please Print): ___________________________________
08/12/21
Author’s Signature: ______________________________ Date: _________
If the Deposit Agreement is executed by the Author’s Representative, the Representative shall separately execute the
Following representation.
I represent that I am authorized by the Author to execute this Deposit Agreement on the behalf of the Author.

08/12/21
Author’s Representative Signature: ___________________ Date: ________

